A long-term follow-up of observation in treatment-free remission in patients with chronic myeloid leukemia

   Introduction. The option of observation without therapy with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients is already included in Russian and international clinical guidelines. Evaluation of long-term follow-up results of treatment free remission (TFR) in CML patients is relevant for the introduction of this approach into routine clinical practice.
   Aim — to demonstrate the outcomes in a long-term follow-up of CML patients who discontinued TKI therapy in the RU-SKI trial.
   Patients and methods. The prospective study included 98 CML patients with TKI therapy duration ≥ 3 years and a deep molecular response (DMR, BCR::ABL1 ≤ 0.01 %) duration ≥ 2 years. TKI therapy was resumed with the loss of a major MR (MMR, BCR::ABL1 > 0,1 %).
   Results. Median time of follow-up after TKI discontinuation was 64 months (range of 51–86 months). Survival without MMR loss at 3 and 5 years after TKI discontinuation was 51 % (CI 41–61 %) and 46 % (CI 36–57 %) respectively. From 3 to 5 years of follow-up without therapy, the loss of MMR occurred in 2 (4 %) patients. There was no MMR loss observed after 5 years of follow-up. In patients with first and second treatment discontinuation, survival without MMR loss was 50 % versus 12,5 %
(р = 0,039). All 50 patients with molecular relapses regained MMR and MR4 after TKI therapy resumption. BCR::ABL1 level fluctuations 0,01–0,1 % were in 62 % (n = 29) patients, who were in TFR at the time of analysis. Loss of MR4 was observed in 38 (42 %) from 90 patients with first TKI discontinuation. Survival without MMR loss from MO4 loss was 24 % at 5 years after TKI discontinuation. Loss of MO4 in the first 3 months after TKI cessation was associated with a high probability of further MMR loss (8 % versus 54 % in patients with loss of MO4 for > 3 months, p = 0.00015).
   Conclusion. The low frequency of late relapses (4 % after 3 years of follow-up) and the possibility of long-term persistence of minimal residual disease (MRD) after discontinuation of therapy determine the need to optimize the timing of molecular monitoring, taking into account the MRD status of patients.

1. Hochhaus A., Larson R.A., Guilhot F., et al. Long term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10): 917–27. DOI: 10.1056/NEJMoa1609324.

2. Bower H., Björkholm M., Dickman P.W., et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24): 2851–7. DOI: 10.1200/JCO.2015.66.2866.

3. Williams L.A., Garcia Gonzalez A.G., Ault P., et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013; 122(5): 641–7. DOI: 10.1182/blood-2013-01-477687.

4. Hochhaus A., Baccarani M., Silver R.T., et al. European LeukemiaNet 2020 recommendations for treating chronic. Leukemia. 2020; 34(3): 966–84. DOI: 10.1038/s41375-020-0776-2.

5. Chai-Adisaksopha C., Lam W., Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A meta-analysis. Leuk Lymphoma. 2016; 57(6): 1300–10. DOI: 10.3109/10428194.2015.1091929.

6. Ionova T.I., Bulieva N.B., Vinogradova O.Yu., et al. Dasatinib in first and second-line therapy of chronic myeloid leukemia: Efficacy, safety and quality of life. Clinical oncohematology. 2017; 10(2): 206–17. DOI: 10.21320/2500-2139-2017-10-2-206-217. (In Russian).

7. Cross N. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009; 22(3): 355–65. DOI: 10.1016/j.beha.2009.04.001.

8. Rea D., Cayuela J.M. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018; 108(4): 355–64. DOI: 10.1007/s12185-017-2295-0.

9. Petrova A.N., Chelysheva E.Yu., Turkina A.G. Treatment-free remission in patients with chronic myeloid leukemia: literature review. Onkogematologiya. 2019; 14(3): 12–22. DOI: 10.17650/1818-8346-2019-14-3-12-22. (In Russian).

10. Rousselot P., Charbonnier A., Cony-Makhoul P., et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014; 32(5): 424–30. DOI: 10.1200/JCO.2012.48.5797.

11. Saussele S., Richter J., Guilhot J., et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018; 19(6): 747–57. DOI: 10.1016/S1470-2045(18)30192-X.

12. Hughes T.P., Ross D.M. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016; 128(1): 17–23. DOI: 10.1182/blood-2016-01-694265.

13. Chelysheva E.Yu., Lazareva O.V., Turkina A.G., et al. Observation in a treatment-free remission in chronic myeloid leukemia patients with a stable deep molecular response in the Russian portion of the international multicenter population based study EUTOS PBS. Gematologiya i transfuziologiya. 2022; 67(3): 351–66. DOI: 10.35754/0234-5730-2022-67-3-351-366. (In Russian).

14. Mahon F-X., Réa D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029–35. DOI: 10.1016/S1470-2045(10)70233-3.

15. Ross D.M., Masszi T., Gómez Casares M.T., et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018; 144(5): 945–54. DOI: 10.1007/s00432-018-2604-x.

16. Rea D., Nicolini F.E., Tulliez M., et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study. Blood. 2017; 129(7): 846–54. DOI: 10.1182/blood-2016-09-742205.

17. Shah N.P., García-Gutiérrez V., Jiménez-Velasco A., et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study. Leuk Lymphoma. 2020; 61(3): 650–9. DOI: 10.1080/10428194.2019.1675879.

18. Clinical recommendations for the diagnosis and treatment of chronic myeloid leukemia. The Ministry of Health of Russia. 2020. URL: http://cr.rosminzdrav.ru/#!/schema/120. (In Russian).

19. Shah N.P. NCCN guidelines updates: Discontinuing TKI therapy in the treatment of chronic myeloid leukemia. J Natl Compr Canc Netw. 2019; 17(5.5): 611–3. DOI: 10.6004/jnccn.2019.5013.

20. Turkina A.G., Petrova A.N., Chelysheva E.Yu., et al. A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. Gematologiya i transfuziologiya.. 2020; 65(4): 370–85. DOI: 10.35754/0234-5730-2020-65-4-370-385. (In Russian).

21. Shukhov O.A., Petrova A.N., Chelysheva E.Yu., et al. Factors for sustaining molecular remission after discontinuation of tyrosine kinase inhibitors therapy in chronic myeloid leukemia: Results of non-randomized prospective clinical trial. Klinicheskaya onkogematologiya. 2021; 14(1): 1–12. DOI: 10.21320/2500-2139-2021-14-1-1-12. (In Russian).

22. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in “goodrisk” chronic granulocytic leukemia. Blood. 1984; 63(4): 789–99.

23. Etienne G., Guilhot J., Rea D., et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017; 35(3): 298–305. DOI: 10.1200/JCO.2016.68.2914.

24. Ross D.M., Pagani I.S., Shanmuganathan N., et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018; 32(12): 2572–9. DOI: 10.1038/s41375-018-0264-0.

25. Zang D.Y., Lee W.S., Mun Y.C., et al. Long-term follow-up after treatment discontinuation in patients with chronic myeloid leukemia: The Korean Imatinib Discontinuation (KID) study. Blood. 2018; 132(S1): 4252. DOI: 10.1182/blood-2018-99-118026.

26. Mahon F.X., Richter J., Hochhaus A., et al. Final analysis of a Pan European STOP Tyrosine Kinase Inhibitor Trial in chronic myeloid leukemia: The EURO-SKI study. Blood. 2021; 138(S1): 633. DOI: 10.1182/blood-2021-148369.

27. Dulucq S., Astrugue C., Etienne G., et al. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: A systematic review of literature with a meta‐analysis of studies over the last ten years. Br J Haematol. 2020; 189(3): 452–68. DOI: 10.1111/bjh.16408.

28. Rousselot P., Loiseau C., Delord M., et al. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020; 4(13): 3034–40. DOI: 10.1182/bloodadvances.2020001772.

29. Richter J., Lübking A., Söderlund S., et al. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR — final report from AFTER-SKI. Leukemia. 2021; 35(8): 2416–8. DOI: 10.1038/s41375-021-01173-w.

30. Legros L., Nicolini F.E., Etienne G., et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017; 123(22): 4403–10. DOI: 10.1002/cncr.30885.

31. Turkina A.G., Chelysheva E.Yu., Shuvaev V.A., et al. Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy. Terapevticheskii arkhiv. 2017; 89(12): 86–96. DOI: 10.17116/terarkh2017891286-96. (In Russian).

32. Kimura S., Imagawa J., Murai K., et al. Treatment-free remission after firstline dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): A single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020; 7(3): e218–25. DOI: 10.1016/S2352-3026(19)30235-2.

33. Okada M., Imagawa J., Tanaka H., et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018; 18(5): 353–60. DOI: 10.1016/j.clml.2018.03.004.

34. Mahon F.X., Boquimpani C., Takahashi N., et al. ENESTop 192-weeks results: Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line nilotinib. Clin Lymphoma Myeloma Leuk. 2019; 19(S1): 288–9. DOI: 10.1200/JCO.2019.37.15_suppl.7005.

35. Ross D.M., Branford S., Seymour J.F., et al. Patients with chronic myeloid leukaemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukaemia by DNA PCR. Leukemia. 2010; 24(10): 1719–24. DOI: 10.1038/leu.2010.185.

36. Ross D., Hughes T.P., Melo J.V. Do we have to kill the last CML cell? Leukemia. 2011; 25(2): 193–200. DOI: 10.1038/leu.2010.197.

37. Mahon F.X., Etienne G. Deep molecular response in chronic myeloid leukemia: The new goal of therapy? Clin Cancer Res. 2014; 20(2): 310–22. DOI: 10.1158/1078-0432.CCR-13-1988.

38. Schepers K., Pietras E.M., Reynaud D., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013; 13(3): 285–99. DOI: 10.1016/j.stem.2013.06.009.

39. Laneuville P. When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Curr Treat Options Oncol. 2018; 19(3): 15. DOI: 10.1007/s11864-018-0532-2.

40. Ilander M., Olsson-Strömberg U., Schlums H., et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017; 31(5): 1108–16. DOI: 10.1038/leu.2016.360.

41. Rea D., Henry G., Khaznadar Z., et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study. Haematologica. 2017; 102(8): 1368–77. DOI: 10.3324/haematol.2017.165001.

42. Molldrem J.J., Lee P.P., Wang C., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000; 6(9): 1018–23. DOI: 10.1038/79526.

43. Schütz C., Inselmann S., Sausslele S., et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017; 31(4): 829–36. DOI: 10.1038/leu.2017.9.

44. Schmidt M., Hochhaus A., König-Merediz S.A., et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol. 2000; 18(19): 3331–8. DOI: 10.1200/JCO.2000.18.19.3331.

45. La Nasa G., Caocci G., Littera R., et al. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 2013; 41(5): 424–31. DOI: 10.1016/j.exphem.2013.01.008.

46. Caocci G., Greco M., Delogu G., et al. Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. J Hematol Oncol. 2016; 9(1): 63. DOI: 10.1186/s13045-016-0293-y.

47. Smirnikhina S.A., Lavrov A.V., Adilgereeva E.P., et al. Clinical significance of the whole exome studies in myeloid neoplasms using next-generation sequencing. Klinicheskaya onkogematologiya. 2013; 6(1): 11–9. (In Russian).